| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adverse event grading: the case of Duffy null-associated neutrophil counts
|
Hibbs, Stephen P
|
|
|
12 |
8 |
p. e567
|
artikel
|
| 2 |
A multimodal sexual dysfunction intervention versus enhanced usual care for survivors of haematopoietic stem-cell transplantation: a single-centre, open-label, randomised clinical trial
|
El-Jawahri, Areej
|
|
|
12 |
8 |
p. e611-e620
|
artikel
|
| 3 |
A new chapter in relapsed or refractory multiple myeloma
|
The Lancet Haematology,
|
|
|
12 |
8 |
p. e561
|
artikel
|
| 4 |
Carfilzomib–lenalidomide–dexamethasone versus lenalidomide–dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial
|
Bringhen, Sara
|
|
|
12 |
8 |
p. e621-e634
|
artikel
|
| 5 |
Clonal haematopoiesis to clonal cytopenias: unravelling disease evolution over time
|
Kirschner, Kristina
|
|
|
12 |
8 |
p. e650-e661
|
artikel
|
| 6 |
Correction to Lancet Haematol 2025; 12: e294–303
|
|
|
|
12 |
8 |
p. e568
|
artikel
|
| 7 |
Direct oral anticoagulant reversal for acute intracranial haemorrhage
|
Marietta, Marco
|
|
|
12 |
8 |
p. e563-e566
|
artikel
|
| 8 |
Enhancing sexual function after haematopoietic transplantation
|
Stratton, Pamela
|
|
|
12 |
8 |
p. e562-e563
|
artikel
|
| 9 |
European Hematology Association 2025 Congress
|
Lai, Cheryl
|
|
|
12 |
8 |
p. e569
|
artikel
|
| 10 |
Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial
|
Mateos, María-Victoria
|
|
|
12 |
8 |
p. e588-e598
|
artikel
|
| 11 |
Intractable hyphaema following cataract surgery and microstent insertion in a patient on zanubrutinib
|
Wood, Alanna
|
|
|
12 |
8 |
p. e662
|
artikel
|
| 12 |
ISTH 2025 Congress
|
Smith, Lan-Lan
|
|
|
12 |
8 |
p. e571
|
artikel
|
| 13 |
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network
|
van de Donk, Niels W C J
|
|
|
12 |
8 |
p. e635-e649
|
artikel
|
| 14 |
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial
|
Hungria, Vania
|
|
|
12 |
8 |
p. e599-e610
|
artikel
|
| 15 |
Research landscape of plasma cell disorders in South Asia: a call for collaboration
|
Mehra, Nikita
|
|
|
12 |
8 |
p. e572-e573
|
artikel
|
| 16 |
18th International Conference on Malignant Lymphoma
|
Marín, Daniela
|
|
|
12 |
8 |
p. e570
|
artikel
|
| 17 |
Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study
|
Kumar, Shaji K
|
|
|
12 |
8 |
p. e574-e587
|
artikel
|
Tijdschrift beschrijving